Condition: Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) · Sponsor: Novartis Pharmaceuticals
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants will be randomized to receive either NIO752 or placebo followed by an open-label extension.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Univ of California San Francisco | San Francisco, California, United States | Recruiting |
| CenExcel Rocky Mtn Clin Research | Englewood, Colorado, United States | Recruiting |
| Mayo Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Novartis Investigative Site | Melbourne, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Caen, France | Recruiting |
| Novartis Investigative Site | Créteil, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Toulouse, France | Recruiting |
| Novartis Investigative Site | Bonn, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Düsseldorf, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Leipzig, Saxony, Germany | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07498426